SSA
EDSA icon

Schonfeld Strategic Advisors’s Edesa Biotech EDSA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,650
Closed -$103K – 2707
2026
Q1 		$103K Buy
+19,650
New +$58.9K ﹤0.01% 1880

Other funds holding EDSA

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Schonfeld Strategic Advisors's EDSA Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Edesa Biotech (EDSA) in Q2 2026, closing a stake of 19,650 shares — an estimated $103K sold.

Schonfeld Strategic Advisors first reported a position in EDSA in Q1 2026 and held it in 1 quarter. The position peaked at $103K in Q1 2026. 30 funds tracked by Wall St. Rank hold EDSA as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Edesa Biotech position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 19,650 Edesa Biotech shares in Q2 2026, an estimated $103K.
  • Schonfeld Strategic Advisors first reported a position in Edesa Biotech in Q1 2026 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Edesa Biotech position peaked at $103K in Q1 2026.
  • 30 funds tracked by Wall St. Rank held Edesa Biotech as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.